Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097968 · ClinicalTrials.gov registry record · Phase 3
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00097968: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00097968 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00097968, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine. The purpose of this study is to evaluate the change in kidney function after beginning everolimus, while determining the most effective Neoral® (cyclosporine) dose to take with everolimus, in adult cardiac transplant patients who have had their transplanted heart for at least 1 year and who have cardiac allograft vasculopathy.
Interventions
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-08 |
| Phase | Phase 3 |
What the finished NCT00097968 record still lists
NCT00097968 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which everolimus is the first listed.
NCT00097968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00097968 about?
NCT00097968 is a clinical study titled "Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy". Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine. The purpose of this study is to evaluate the change in kidney function...
What is the current status of trial NCT00097968?
This trial is currently completed. It is a Phase 3 study. The study started on 2004-08.
What interventions are being tested in trial NCT00097968?
The interventions under investigation include: everolimus (DRUG).
Who is sponsoring clinical trial NCT00097968?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia